220 related articles for article (PubMed ID: 2742363)
1. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
[TBL] [Abstract][Full Text] [Related]
2. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA
J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634
[TBL] [Abstract][Full Text] [Related]
3. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
5. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
6. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549
[No Abstract] [Full Text] [Related]
7. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
[TBL] [Abstract][Full Text] [Related]
8. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
Admani AK; Verma S; Cordingley GJ; Harris RI
Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
[TBL] [Abstract][Full Text] [Related]
9. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Mizuno Y; Yoshida M; Obayashi T; Ueki A
Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
[No Abstract] [Full Text] [Related]
10. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Poewe WH; Lees AJ; Stern GM
Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
[TBL] [Abstract][Full Text] [Related]
11. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
Messiha FS; Hsu TH; Bianchine JR
J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
[TBL] [Abstract][Full Text] [Related]
12. [L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism].
Arai H; Shinotoh H; Hattori T
Rinsho Shinkeigaku; 1997 Mar; 37(3):264-5. PubMed ID: 9217430
[TBL] [Abstract][Full Text] [Related]
13. Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
Tayarani-Binazir KA; Jackson MJ; Strang I; Jairaj M; Rose S; Jenner P
Behav Pharmacol; 2012 Apr; 23(2):126-33. PubMed ID: 22236652
[TBL] [Abstract][Full Text] [Related]
14. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
[TBL] [Abstract][Full Text] [Related]
15. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Dessibourg CA; Gachoud JP
Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
[TBL] [Abstract][Full Text] [Related]
16. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336
[No Abstract] [Full Text] [Related]
17. Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
Boomsma F; van den Meiracker A; Man in 't Veld A; Schalekamp M
Life Sci; 1995; 57(19):1753-9. PubMed ID: 7475917
[TBL] [Abstract][Full Text] [Related]
18. [The L-dopa test in Parkinson's disease].
Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
Streifler M; Vardi J; Kesten M
Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
[No Abstract] [Full Text] [Related]
20. Treating parkinsonism with L-dopa and carboxylase inhibitor.
Shau-Fong K; Ho YM
Mod Med Asia; 1977 Sep; 13(9):23-5. PubMed ID: 600260
[No Abstract] [Full Text] [Related]
[Next] [New Search]
